Altamira Therapeutics Valuation
| CYTO Stock | USD 0.40 0.02 4.76% |
Altamira Therapeutics is overvalued. Altamira Therapeutics shows a prevailing Real Value of $0.39 per share. The current price of the firm is $0.4. Our model approximates the value of Altamira Therapeutics from analyzing the firm fundamentals such as Return On Equity of -3.69, shares owned by insiders of 0.52 %, and Current Valuation of 1.95 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Altamira Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Altamira Therapeutics is based on 3 months time horizon. Increasing Altamira Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Altamira Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Altamira Stock. However, Altamira Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.4 | Real 0.39 | Hype 0.39 | Naive 0.43 |
The intrinsic value of Altamira Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Altamira Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Altamira Therapeutics helps investors to forecast how Altamira stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Altamira Therapeutics more accurately as focusing exclusively on Altamira Therapeutics' fundamentals will not take into account other important factors: Altamira Therapeutics Total Value Analysis
Altamira Therapeutics is currently anticipated to have valuation of 1.95 M with market capitalization of 1.59 M, debt of 99.66 K, and cash on hands of 984.19 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Altamira Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.95 M | 1.59 M | 99.66 K | 984.19 K |
Altamira Therapeutics Asset Utilization
One of the ways to look at asset utilization of Altamira is to check how much profit was generated for every dollar of assets it reports. Altamira Therapeutics shows a negative utilization of assets of -0.57 percent, losing $0.005715 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Altamira Therapeutics shows how discouraging it operates for each dollar spent on its assets.Altamira Therapeutics Ownership Allocation
Almost 96.35 percent of Altamira Therapeutics outstanding shares are held by general public with 0.52 (percent) owned by insiders and only 3.13 % by other corporate entities.Altamira Therapeutics Profitability Analysis
Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M).About Altamira Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Altamira Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Altamira Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Altamira Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Altamira Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Altamira Therapeutics. We calculate exposure to Altamira Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Altamira Therapeutics's related companies.Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. Altamira Therapeutics is traded on NASDAQ Exchange in the United States.
Altamira Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 491.3 K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.